Urologic Imaging

What Is the Best Imaging for Staging High-Risk Prostate Cancer?

·
What Is the Best Imaging for Staging High-Risk Prostate Cancer?

A 68-year-old man sits in your urology clinic, his recent biopsy report on the desk. The pathology confirms prostate adenocarcinoma, Gleason score 4+4=8, and his prostate-specific antigen (PSA) is 22 ng/mL. This is clinically established high-risk prostate cancer, and the next critical step is accurate staging to determine the extent of the disease and guide a definitive treatment plan. You need to know if the cancer is confined to the prostate, has spread locally, or has metastasized to lymph nodes or bone. This article details the American College of Radiology (ACR) recommended imaging workflow for this specific clinical scenario, focusing on why certain studies are chosen over others. For staging high-risk prostate cancer, the ACR rates MRI abdomen and pelvis without and with IV contrast as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to patients with newly diagnosed, biopsy-proven prostate cancer classified as high-risk. High-risk disease is typically defined by the presence of at least one of the following features:

  • A Gleason score of 8, 9, or 10.
  • A serum PSA level greater than 20 ng/mL.
  • A clinical stage of T2c or higher, indicating a tumor that is palpable in both lobes of the prostate.

This workflow is for initial staging before any treatment has been administered. It is crucial to distinguish this scenario from others that require different imaging strategies. This guidance does not apply to:

  • Patients with low-risk or intermediate-risk prostate cancer: These patients, particularly those with low-risk disease, may not require staging imaging at all, as the likelihood of metastatic disease is very low. Many are candidates for active surveillance.
  • Patients with suspected prostate cancer who are biopsy-naïve: The initial diagnostic workup before a biopsy is a separate clinical question.
  • Patients with biochemical recurrence after treatment: Imaging to detect recurrent disease after prostatectomy or radiation therapy involves different modalities, often relying on advanced PET imaging.

What Diagnoses Are You Working Up in This Scenario?

For a patient with established high-risk prostate cancer, the primary diagnosis is already known. The purpose of staging imaging is to determine the anatomic extent of the disease, which is the most critical factor in treatment planning. The imaging workup is designed to differentiate between several key stages of disease spread.

Extraprostatic Extension (EPE) and Seminal Vesicle Invasion (SVI): A primary goal is to assess whether the tumor has breached the prostatic capsule (EPE) or invaded the adjacent seminal vesicles (SVI). The presence of either finding upstages the tumor to T3 disease and significantly impacts surgical planning and radiotherapeutic field design. It often indicates a higher risk of recurrence and may prompt consideration of adjuvant therapy.

Pelvic Lymph Node Metastasis: The next step in cancer progression is typically spread to regional (pelvic) lymph nodes. Identifying nodal involvement (N1 disease) is critical, as it may make a patient a poor candidate for local-only therapy like surgery and instead favor systemic treatments combined with radiation.

Distant Metastatic Disease: High-risk prostate cancer has a substantial propensity to spread beyond the pelvis, most commonly to the bones (osseous metastases) but also to non-regional lymph nodes or visceral organs. Detecting distant metastases (M1 disease) fundamentally changes the treatment goal from curative local therapy to systemic management of metastatic disease.

Why Is MRI Abdomen and Pelvis Without and With IV Contrast a Recommended Study?

The ACR designates MRI abdomen and pelvis without and with IV contrast as a Usually Appropriate study for staging high-risk prostate cancer. Its strength lies in its superior soft-tissue contrast, which provides detailed anatomical information crucial for local and regional staging without using ionizing radiation (0 mSv).

The pelvic portion of the MRI, ideally performed using a multiparametric protocol (mpMRI), is unparalleled for evaluating the primary tumor. It can accurately delineate the tumor’s size, location, and relationship to the prostatic capsule, neurovascular bundles, and seminal vesicles. This information is vital for assessing the likelihood of EPE and SVI, which directly informs surgical approach and prognosis. The use of IV contrast enhances the detection of tumor extension and nodal involvement.

Extending the field of view to include the entire abdomen allows for the evaluation of retroperitoneal and other non-pelvic lymph nodes, providing more comprehensive regional staging than a pelvis-only MRI.

While MRI is a cornerstone, it’s important to understand the role of other Usually Appropriate studies:

  • PSMA PET/CT: This advanced imaging modality is highly sensitive and specific for detecting prostate cancer metastases in lymph nodes and bone, often outperforming conventional imaging. For high-risk staging, PSMA PET/CT skull base to mid-thigh is also rated Usually Appropriate and is increasingly used as a single, comprehensive staging examination. The choice between MRI/Bone Scan and PSMA PET/CT may depend on institutional availability and multidisciplinary consensus.
  • Bone Scan: A whole-body technetium-99m bone scan is also rated Usually Appropriate and has long been the standard for detecting osseous metastases. It is highly sensitive for sclerotic bone lesions typical of prostate cancer. It is often performed in conjunction with a CT or MRI of the abdomen and pelvis to provide complete soft tissue and bone staging.
  • CT Abdomen and Pelvis with IV Contrast: While also rated Usually Appropriate, CT provides less detailed evaluation of the primary tumor compared to MRI. Its primary role is in detecting lymphadenopathy and visceral metastases. It is a reasonable alternative when MRI is contraindicated or unavailable.

What’s Next After MRI? Downstream Workflow

The results of the staging MRI, often combined with a bone scan or PSMA PET/CT, will directly guide the patient’s management plan in a multidisciplinary setting.

  • If imaging shows disease confined to the prostate: The patient is considered to have localized high-risk disease. They are typically a candidate for definitive local therapy with curative intent, such as a radical prostatectomy with extended pelvic lymph node dissection or external beam radiation therapy, often combined with androgen deprivation therapy (ADT).
  • If imaging shows extraprostatic extension, seminal vesicle invasion, or pelvic lymph node involvement: This indicates locally advanced disease. Treatment often involves a combination of modalities. For example, a patient might receive radiation therapy with long-term ADT. If surgery is considered, the patient must be counseled on the higher risk of positive margins and the likely need for adjuvant radiation.
  • If imaging shows distant metastatic disease (e.g., in bone or non-regional nodes): The treatment paradigm shifts from local control to systemic therapy. The mainstay of treatment is typically ADT, potentially intensified with newer hormonal agents or chemotherapy. Palliative radiation may be used for symptomatic bone lesions.
  • If imaging is indeterminate: An equivocal finding, such as a borderline-sized lymph node or an ambiguous bone lesion, may require further investigation. This could involve a short-interval follow-up scan, a biopsy of the suspicious lesion, or proceeding with the planned treatment while accounting for the uncertainty (e.g., by extending a radiation field or performing a more extensive lymph node dissection).

Pitfalls to Avoid (and When to Get Help)

Accurate staging in high-risk prostate cancer is critical, and several common pitfalls can lead to suboptimal management.

  • Imaging too soon after biopsy: Post-biopsy hemorrhage can create artifacts on MRI that mimic or obscure tumor, potentially leading to over-staging or under-staging of EPE. It is generally recommended to wait at least 6-8 weeks after biopsy before performing a staging MRI.
  • Incomplete staging: Relying solely on a pelvic MRI without assessing for distant disease is a significant error in high-risk patients. The workup must include an evaluation for osseous metastases, typically with a bone scan or a PSMA PET scan.
  • Underestimating the value of mpMRI: Ordering a generic pelvic MRI without specifying a multiparametric prostate protocol may result in a non-diagnostic or incomplete study for local staging.
  • Ignoring contraindications: Ensure the patient has no contraindications to IV gadolinium-based contrast agents, such as severe renal insufficiency or a known allergy.

If staging results are complex, equivocal, or discordant with the clinical picture, discussion at a multidisciplinary tumor board with urology, radiation oncology, medical oncology, and radiology is the best path forward.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a comprehensive overview of imaging across all prostate cancer presentations, from initial detection to surveillance, please consult our parent guide. For additional resources on applying appropriateness criteria and understanding imaging techniques, the following tools are available.

Frequently Asked Questions

Why is MRI preferred over CT for local staging of high-risk prostate cancer?

MRI offers significantly better soft-tissue resolution than CT, allowing for detailed evaluation of the prostate gland itself. This is critical for assessing extraprostatic extension (EPE) and seminal vesicle invasion (SVI), two key factors in local staging that heavily influence treatment decisions. CT is primarily used for detecting lymph node enlargement and cannot reliably visualize disease extent within and just outside the prostate.

If PSMA PET/CT is also ‘Usually Appropriate’, when should I choose it over the MRI and bone scan combination?

PSMA PET/CT is a highly sensitive, single-test modality for detecting nodal and distant metastases and is increasingly used as the primary staging tool. It may be preferred when there is a very high risk of metastatic disease, as it can detect smaller metastatic sites than conventional imaging. The choice often depends on institutional availability, cost, and multidisciplinary team preference. An MRI is still considered excellent for detailed local T-staging of the primary tumor.

Is a bone scan always necessary if I order an MRI of the abdomen and pelvis?

Yes, in the context of conventional imaging, a bone scan is considered a complementary and necessary part of the workup for high-risk disease. While MRI can detect bone marrow replacement from metastases, a whole-body bone scan is a dedicated and validated test for systematically screening the entire skeleton for osseous metastases, which is the most common site of distant spread. The alternative is to perform a single, comprehensive PSMA PET/CT scan.

Does the patient need IV contrast for the staging MRI?

Yes, the ACR recommends an MRI of the abdomen and pelvis without and with IV contrast. The dynamic contrast-enhanced (DCE) portion of a multiparametric MRI protocol helps in identifying and characterizing suspicious areas within the prostate and can improve the detection of extraprostatic extension and involved lymph nodes.

What if my patient has a contraindication to MRI, like an incompatible pacemaker?

If a patient cannot undergo an MRI, the alternative Usually Appropriate study is a CT of the abdomen and pelvis with IV contrast, paired with a whole-body bone scan. While CT is less sensitive for local T-staging, it can effectively assess for pelvic lymphadenopathy and visceral metastases, and the bone scan will complete the evaluation for osseous disease. A PSMA PET/CT would also be an excellent alternative in this situation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026